Alexis Kays Leonard

US Patent:

20060003989, Jan 5, 2006

Filed:

Apr 22, 2005

Appl. No.:

11/112950

Inventors:

Steven Quay - Edmonds WA, US
Henry Costantino - Woodinville WA, US
Michael Houston - Sammamish WA, US
Alexis Leonard - Maple Valley WA, US

International Classification:

A61K 31/55

US Classification:

514214030

Abstract:

Methods and compositions of the invention employ acetylcholinesterase (ACE) inhibitors to prevent and treat diseases and other disorders of the central nervous system (CNS), including Alzheimer's disease. ACE inhibitors are administered for targeted delivery to the CNS, for example by intranasal delivery. The methods and compositions of the present invention yield therapeutic concentrations of ACE inhibitors in a CNS tissue or compartment without the attendant disadvantages, risks and side effects of oral or injection delivery. Exemplary ACE inhibitors for use within the invention include galantamine and various salts and derivatives of galantamine. Carboxylate salts of galantamine (e.g., galantamine gluconate, galantamine lactate, galantamine citrate and galantamine glucarate) described herein exhibit a significant increase in solubility compared to other forms of galantamine, such as galantamine hydrobromide.

US Patent:

20060210614, Sep 21, 2006

Filed:

May 4, 2006

Appl. No.:

11/418982

Inventors:

Steven Quay - Seattle WA, US
Alexis Leonard - Maple Valley WA, US
Henry Costantino - Woodinville WA, US

International Classification:

A61K 9/127
A61F 13/02
A61K 38/22
A61K 31/56

US Classification:

424448000, 514012000, 424450000, 514171000

Abstract:

Methods for treating metabolic diseases are described for intranasal delivery of an exenatide, comprising an aqueous mixture of exendin, and a delivery enhancer selected from the group consisting of a solubilizer, a chelator, and a surfactant, and the pharmaceutical formulations used therein.

US Patent:

20070032410, Feb 8, 2007

Filed:

Sep 29, 2006

Appl. No.:

11/537468

Inventors:

Steven Quay - Seattle WA, US
Alexis Leonard - Maple Valley WA, US
Henry Costantino - Woodinville WA, US
Anthony Sileno - Brookhaven Hamlet NY, US
Joshua Sestak - Kirkland WA, US

International Classification:

A61K 38/22

US Classification:

514009000, 514012000

Abstract:

Methods and compositions containing oxytocin or an oxytocin analog, specifically carbetocin, are provided for the prevention and treatment of autism spectrum disorders, related disorders and symptoms of such disorders. The methods and compositions of the invention are effective in the treatment of social withdrawal, eye contact avoidance, repetitive behaviors, anxiety, attention deficit, hyperactivity, depression, loss of speech, verbal communication difficulties, aversion to touch, visual difficulties, comprehension difficulties, and sound and light sensitivity. Additional compositions and methods are provided which employ oxytocin or an oxytocin analog in combination with a secondary or adjunctive therapeutic agent to yield more effective treatment tools against autism spectrum disorders and related disorders.

US Patent:

20080234200, Sep 25, 2008

Filed:

May 20, 2008

Appl. No.:

12/124050

Inventors:

Steven C. Quay - Woodinville WA, US
Alexis Kays Leonard - Maple Valley WA, US
Henry R. Costantino - Woodinville WA, US

Assignee:

NASTECH PHARMACEUTICAL COMPANY INC. - Bothell WA

International Classification:

A61K 38/17
A61P 3/00

US Classification:

514 12

Abstract:

Methods for treating metabolic diseases are described for intranasal delivery of an exenatide, comprising an aqueous mixture of exendin, and a delivery enhancer selected from the group consisting of a solubilizer, a chelator, and a surfactant, and the pharmaceutical formulations used therein.

US Patent:

20080318837, Dec 25, 2008

Filed:

Dec 1, 2006

Appl. No.:

12/095801

Inventors:

Steven C. Quay - Seattle WA, US
Henry R. Costantino - Woodinville WA, US
Michael V. Templin - Bothell WA, US
Alexis Kays Leonard - Maple Valley WA, US
Mary S. Kleppe - Snohomish WA, US
Joshua O. Sestak - Kirkland WA, US

Assignee:

NASTECH PHARMACEUTICAL COMPANY INC. - Bothell WA

International Classification:

A61K 38/00

US Classification:

514 2

Abstract:

What is described is a pharmaceutical formulation comprising a mixture of a pharmaceutically effective amount of glucose-regulating peptide (GRP) and enhancers, wherein the pharmaceutical formulation is used in the treatment of a metabolic syndrome.

US Patent:

20080318861, Dec 25, 2008

Filed:

Dec 7, 2006

Appl. No.:

12/096650

Inventors:

Steven C. Quay - Seattle WA, US
Henry R. Costantino - Woodinville WA, US
Alexis Kays Leonard - Maple Valley WA, US

Assignee:

NASTECH PHARMACEUTICAL COMPANY INC. - Bothell WA

International Classification:

A61K 38/22
A61P 3/10

US Classification:

514 12

Abstract:

What is described is a pharmaceutical formulation for intranasal administration of exendin to a mammal, wherein the formulation comprises a therapeutically effective amount of an exendin, a viscosity enhancer, methyl-β-cyclodextrin, a surfactant, tartrate buffer to control pH and a chelating agent for cations, and wherein such exendin dosage form exhibits at least 95% exenatide recovery after storage for at least 365 days at 5 C.

US Patent:

20100311655, Dec 9, 2010

Filed:

Sep 28, 2007

Appl. No.:

12/599267

Inventors:

Alexis Kays Leonard - Maple Valley WA, US
Joshua O. Sestak - Lawrence KS, US
Henry R. Costantino - Woodinville WA, US
Anthony P. Sileno - Brookhaven Hamlet NY, US
Lalit Raj Peddakota - San Diego CA, US
Kayvon Emile Sharghi - Seattle WA, US
Garland M. Bellamy - Bothell WA, US
Jason Philip Gesty - Seattle WA, US

Assignee:

MDRNA, INC. - Bothell WA

International Classification:

A61K 38/11
A61P 25/22
A61P 25/24
A61P 25/18

US Classification:

514 116

Abstract:

Methods and compositions containing oxytocin or an oxytocin analog, such as carbetocin, are provided for the prevention and treatment of autism spectrum disorders, related disorders and symptoms of such disorders. The methods and compositions of this disclosure are effective in the treatment of social withdrawal, eye contact avoidance, repetitive behaviors, anxiety, attention deficit, hyperactivity, depression, loss of speech, verbal communication difficulties, aversion to touch, visual difficulties, comprehension difficulties, and sound and light sensitivity. Additional compositions and methods are provided which employ oxytocin or an oxytocin analog in combination with a secondary or adjunctive therapeutic agent to yield more effective treatment tools against autism spectrum disorders and related disorders.

US Patent:

20120172304, Jul 5, 2012

Filed:

Aug 5, 2011

Appl. No.:

13/204485

Inventors:

Alexis Kays LEONARD - Maple Valley WA, US
Joshua Orion SESTAK - Lawrence KS, US
Henry R. COSTANTINO - Woodinville WA, US
Anthony P. SILENO - Mendham NY, US
Lalit Raj PEDDAKOTA - San Diego CA, US
Kayvon Emile SHARGHI - Chevy Chase MD, US
Garland M. BELLAMY - Santa Fee NM, US
Jason Philip GESTY - Seattle WA, US
Steven C. QUAY - Seattle WA, US

International Classification:

A61K 38/11
A61P 25/28
A61P 25/24
A61P 25/00
A61P 25/22

US Classification:

514 116

Abstract:

Methods and compositions containing oxytocin or an oxytocin analog, such as carbetocin, are provided for the prevention and treatment of autism spectrum disorders, related disorders and symptoms of such disorders. The methods and compositions of this disclosure are effective in the treatment of social withdrawal, eye contact avoidance, repetitive behaviors, anxiety, attention deficit, hyperactivity, depression, loss of speech, verbal communication difficulties, aversion to touch, visual difficulties, comprehension difficulties, and sound and light sensitivity. Additional compositions and methods are provided which employ oxytocin or an oxytocin analog in combination with a secondary or adjunctive therapeutic agent to yield more effective treatment tools against autism spectrum disorders and related disorders.